

PCRS reimbursement data for pregabalin and gabapentin on both GMS and DPS schemes from January 2011 to July 2013




Figure 1: Total DPS and GMS ingredient cost on gabapentin and pregabalin from January 2011 to July 2013.




Figure 2: Total DPS and GMS expenditure (includes mark-ups and margins) on gabapentin and pregabalin from January 2011 to July 2013.




Figure 3: Total number of patients (DPS and GMS) on gabapentin and pregabalin from January 2011 to July 2013




Figure 4: Total number of prescriptions (DPS and GMS) on gabapentin and pregabalin from January 2011 to July 2013

Note: In November 2012 pregabalin underwent a price reduction.